PDL BioPharma, Inc. (NASDAQ:PDLI)

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.

PDL BioPharma, Inc. (NASDAQ:PDLI)’s Financial Overview

PDL BioPharma, Inc. (NASDAQ:PDLI) declined -4.37% yesterday to close its trading session at $2.19. The company has 1 year Price Target of $3.5. PDL BioPharma, Inc. has 52-Week high of $3.95 and 52-Week Low of $2.14. The stock touched its 52-Week High on Dec 17, 2015 and 52-Week Low on Nov 30, 2016. The stock traded with the volume of 5.27 Million shares yesterday. The firm shows the market capitalization of $362.58 Million.

PDL BioPharma, Inc. (NASDAQ:PDLI) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $0.11/share against the analyst consensus estimate of $0.08/share. The difference between the actual and expected EPS is $0.03 a share with a surprise factor of 37.5%.

The firm is trading with SMA20 of -29.08 Percent, SMA50 of -31.37 Percent and SMA200 of -31.55 percent. PDL BioPharma, Inc. has P/S value of 1.02 while its P/B value stands at 0.48. Similarly, the company has Return on Assets of 16.1 percent, Return on Equity of 23.9 percent and Return on Investment of 37.8 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 85.7 percent respectively.

Many brokerage firms are involved in issuing their ratings on PDL BioPharma, Inc. (NASDAQ:PDLI). On 20-Jan-11 RBC Capital Mkts Upgrade PDL BioPharma, Inc. Stock  to Outperform. Another firm also rated the stock on 10-Sep-10 where RBC Capital Mkts Initiated the stock to Sector Perform.

The Stock currently has Analyst’ mean Recommendation of 3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +59.82% increase from the last price of 2.19.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Weatherford International plc (NYSE:WFT)

Weatherford International is one of the world’s leading providers of equipment and services used for the drilling, completion and production of oil and natural gas wells. Its operations are conducted in numerous countries and it has service and sales locations in substantially all of the oil and natural gas producing regions in the world. The company’s products and services are divided into the following four principal operating divisions: Drilling and Intervention Services; Completion Systems; Artificial Lift Systems; and Compression Services.

Weatherford International plc (NYSE:WFT)’s Financial Outlook

The 32 analysts offering 12-month price forecasts for Weatherford International PLC have a median target of 7.00, with a high estimate of 13.00 and a low estimate of 3.00. The median estimate represents a +36.99% increase from the last price of 5.11.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Weatherford International plc has a Consensus Recommendation of 1.95. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock gained 18.29% and closed its last trading session at $5.11. The company has the market capitalization of $5.01 Billion. The stock has 52-week high of $11.05 and 52-Week low of $3.73. The firm touched its 52-Week high on Dec 3, 2015 and 52-Week low on Nov 8, 2016. The company has volume of 57.87 Million shares. The company has a total of 980.98 Million shares outstanding.

Weatherford International plc (NYSE:WFT) in the last quarter reported its actual EPS of $-0.39/share where the analyst estimated EPS was $-0.25/share. The difference between the actual and Estimated EPS is $-0.14. This shows a surprise factor of -56 percent.

The company has YTD performance of -39.09 percent. Beta for Weatherford International plc stands at 2.28 while its ATR (average true range) is 0.44. The company has Weekly Volatility of 7.53%% and Monthly Volatility of 9.72%%.

Weatherford International plc has distance from 20-day Simple Moving Average (SMA20) of 10.5%, Distance from 50-Day Simple Moving Average of -3.64 percent and Distance from 200-Day Simple Moving Average of -15.55%.

The Company currently has ROA (Return on Assets) of -28.9 percent, Return on Equity (ROE) of -105.6 Percent and Return on Investment (ROI) of -11.9% with Gross margin of 7.5 percent and Operating & Profit margin of -45.4% and -63.7% respectively.